Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of ...

NDAQ:ATOS) Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025 ...

Patients in the Veritac-2 study were randomized to receive a standard estrogen blocker called fulvestrant, or Arvinas' ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

The general mood among these heavyweight investors is divided, with 36% leaning bullish and 42% bearish. Among these notable ...

The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new ...

Eli Lilly’s Verzenio is already one of its fastest-growing products, but could go up another gear following a pair of FDA approvals that expand its eligible patient population – particularly ...

After selling its PI3Kα program to Eli Lilly, Scorpion will spinout out a different entity, which will be owned by the ...

The 1976 movie All the President's Men perhaps provided one of the best three-word investing strategies around: "Follow the ...

Eli Lilly and Co. announced Monday that it is buying Boston-based Scorpion Therapeutics and its targeted breast cancer ...

Welcome to the Novartis presentation at the 43rd JPMorgan Healthcare Conference. I'm Richard Vosser, European pharma analyst with JPMorgan. It's my great pleasure to introduce Vas Narasimhan, the CEO ...

Meanwhile, Lilly claims other key growth drivers, including autoimmune disease drug Taltz and cancer drug Verzenio. The commercialization of its Alzheimer's disease drug Kisunla is still in the ...